BiovelocITA
BiovelocITA is the first Italian biotech accelerator, founded in 2015 by Sofinnova Partners and dedicated to transforming promising research into breakthrough biotech companies. The accelerator was co-founded and will be managed by two Italian repeat entrepreneurs with an outstanding track record: Silvano Spinelli, Chairman, and Gabriella Camboni, CEO. Silvano and Gabriella founded EOS, which they sold in 2013 to Clovis Oncology for $470 million. Prior to that they founded Novuspharma, which went public on the Italian Nuovo Mercato in 2000. Sofinnova Partners invested and backed both companies from the start. BiovelocITA brings together best-in-class scientists, entrepreneurs and investors to foster the development of pioneering companies.
Sector
Biopharmaceuticals
Location
Milan
Strategies
Biovelocita
Website
www.biovelocita.com
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.